Current Approaches for New TB Drugs

ISSN: 1875-6387 (Online)
ISSN: 1573-398X (Print)


Volume 10, 4 Issues, 2014


Download PDF Flyer




Current Respiratory Medicine Reviews

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Joseph Varon
The University of Texas Health Science Center
Houston, TX
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Current Approaches for New TB Drugs

Author(s): Shilpika Pandey, Isha Soni, Neha Topno, Arunava Dasgupta and Sidharth Chopra

Affiliation: Division of Microbiology, CSIR-Central Drug Research Institute, B.S. 10/1, Sector 10, Janakipuram Extension, Sitapur Road, Lucknow - 226031, India.

Abstract

Tuberculosis is essentially a curable disease but inspite of a WHO approved DOTS therapy, it still continues to ravage mankind. This situation is exacerbated by long course of chemotherapy, increasing drug resistance and co-emergence with HIV. The TB drug pipeline remained stagnant for a long time with no new drug approved till FDA approval for Bedaquiline. This situation has now improved with a number of agents in pre-clinical and clinical development against M. tuberculosis. In this review, we are focusing on some of the newer drugs in discovery and preclinical development against M. tuberculosis.




Keywords: Clinical strains, drugs, MIC, Mycobacterium, pre-clinical development, tuberculosis.

Download Free Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 10
Issue Number: 2
First Page: 88
Last Page: 96
Page Count: 9
DOI: 10.2174/1573398X10666140813201210
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science